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Abstract
Background: Impaired fibrinolysis is found in impaired glucose tolerance and type 2 diabetes,
associated with components of the metabolic syndrome. There are no data concerning fibrinolysis
in subjects with normal glucose tolerance that convert to diabetes.
Methods:  We studied the activities of tissue plasminogen activator (tPA) and plasminogen
activator inhibitor-1 (PAI-1) and the levels of tPA antigen (a marker of endothelial dysfunction) in
551 subjects with normal glucose tolerance in 1990 in relation to incident diabetes during nine
years of follow-up.
Results: Subjects with diabetes at follow-up (n = 15) had significantly lower baseline tPA activity
and higher PAI-1 activity and tPA antigen than non-converters. The risk of diabetes increased
linearly across quartiles of PAI-activity (p = 0.007) and tPA antigen (p < 0.001) and decreased across
quartiles of tPA activity (p = 0.026). The risk of diabetes with low tPA activity or high PAI-1 activity
persisted after adjustment for age and sex but diminished to a non-significant level after further
adjustments. The odds ratio of diabetes for high tPA antigen was 10.4 (95% confidence interval 2.7–
40) adjusted for age and sex. After further adjustment for diastolic blood pressure, waist
circumference, insulin, triglycerides, fasting and post load glucose the odds ratio was 6.5 (1.3–33, p
= 0.024).
Conclusions: Impaired fibrinolysis and endothelial dysfunction are evident in subjects with normal
glucose tolerance who later develop diabetes. High tPA antigen is predictive of future diabetes
independent from the metabolic syndrome.
Background
The risk of stroke and myocardial infarction is considera-
bly increased in subjects with diabetes [1]. Already at the
time of diagnosis of type 2 diabetes, many patients have
manifest cardiovascular disease (CVD) [2]. This could be
due to a long presymtomatic period with increased
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glucose level as evident by the increased CVD risk already
present with impaired glucose tolerance (IGT) [3,4]. Thus,
interest has focused on factors, not only glucose levels, in
the prediabetic state that would increase the atherothrom-
botic process [5]. A common, possibly genetic, antecedent
of both type 2 diabetes and CVD has been proposed as the
"common soil" hypotheses [6,7].
Recently, markers of inflammation, such as highly sensi-
tive C-reactive protein, have been found to predict type 2
diabetes in long-time follow up of population samples,
although adjusting for measurements of obesity attenu-
ates the relationship [8-12]. Such markers are weakly
related to variables reflecting endothelial function such as
adhesion molecules and von Willebrant factor [13].
In a large population-based study, also increased plasma
levels of plasminogen activator inhibitor-1 (PAI-1) were
strongly related to the development of diabetes independ-
ent from insulin resistance and obesity [8]. The possibility
of elevated PAI-1 being a very early risk marker of the insu-
lin resistance syndrome and diabetes was raised. Further-
more, haemostatic variables related to endothelial
function, such as von Willebrant factor and factor VIII,
also predicted diabetes, especially in women [14]. Data
are lacking regarding other aspects of the fibrinolytic sys-
tem and the development of diabetes, such as the activi-
ties of PAI-1 and tissue plasminogen activator (tPA) or the
mass concentration of the endothelial-derived tPA ("tPA
antigen"), factors related to CVD [15-19]
Thus, there are two questions related to fibrinolytic varia-
bles and the development of diabetes. Firstly, do subjects
with normal glucose tolerance, who later convert to diabe-
tes, have disturbances in the fibrinolytic system and
endothelial function that could explain their increased
risk of CVD even before diabetes ensues? If so, do these
changes predict future diabetes, independent of the influ-
ence of the insulin resistance syndrome, thereby pointing
to other pathways to the diabetic state such as endothelial
dysfunction?
We studied fibrinolytic activity, as measured by tPA and
PAI-1 activity, and a marker of endothelial dysfunction, as
measured by tPA antigen, in a population sample with
normal glucose tolerance at baseline and analysed data
according to conversion to diabetes or not over nine years
of follow-up.
Methods
This study was performed within the framework of the
Northern Sweden MONICA study [20]. In 1990 a popula-
tion sample was screened for cardiovascular risk factors. A
total of 2,000 randomly selected subjects aged 25 to 64
years were invited. In all, 1,583 persons participated (79.2
%). A 75-gram oral glucose tolerance test (OGTT) was per-
formed after an overnight fast in a randomly selected sub-
set of subjects without known diabetes [21,22]. Venous
plasma glucose samples were analysed by the hexokinase
method (Boehringer Mannheim Automated Analysis for
BM/Hitachi System 717). Glucose tolerance was classified
according to WHO criteria from 1999 [23]:
Normal glucose tolerance (NGT) – fasting glucose <7
mmol/L and post load glucose <7.8 mmol/L,
Impaired glucose tolerance (IGT) – fasting glucose <7
mmol/L and post load glucose 7.8–11.0 mmol/L, and
Diabetes – fasting glucose ≥7.0 mmol/L and/or post load
glucose ≥11.1 mmol/L.
Weight was measured with a balance scale to the nearest
0.2 kg, and height was measured to the nearest centimetre.
BMI was calculated as total body weight (kg) / height
(m2). Waist circumference was measured midway
between the lower rib margin and the iliac crest, which in
most occasions was identical with the level of the umbili-
cus. All measurements were done in a standing position
while breathing normally, and participants were asked to
wear light underwear and remove shoes. For the measure-
ment of waist circumference, the recording was done after
a gentle breath-out.
Blood sampling and OGTT took place before noon, after
an overnight fast. tPA and PAI-1 activities were deter-
mined by chromogenic assays, Spectrolyse/fibrin and
Spectrolyse/pl kit (Biopool AB, Umeå, Sweden), respec-
tively. tPA antigen was measured by an enzyme-linked
immunosorbent assay method (TintElize tPA, Biopool
AB). Details regarding assay imprecision and analytical
sensitivity have been published [24]. Serum insulin was
determined by radio immunoassay with a double-anti-
body solid-phase technique (Phadaseph Insulin RIA,
Pharmacia Diagnostics AB, Uppsala, Sweden)
In 1999, all participants, alive and still living in the area,
were recalled for a follow-up examination. The same ques-
tionnaire and anthropometrical measurements as in the
baseline survey were used. Altogether 1,148 (72.5 %) sub-
jects turned up for re-examination. Subjects who previ-
ously had performed an OGTT with normal or impaired
glucose tolerance, and answered no to the question "Do
you have diabetes mellitus?" were once more offered an
OGTT.
Participants, who denied having diabetes in the baseline
survey and answered affirmative to the question "Do you
have diabetes mellitus?" at follow up, were defined as
incident cases of known diabetes mellitus according thoCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/19
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the WHO criteria from 1999 [23]. In November 2002, a
questionnaire exploring details related to the diagnosis of
diabetes, and to the type and duration of current hypogly-
caemic treatment was sent to them. Case records were
scrutinised to confirm diabetes diagnosis and time for
start of insulin therapy. An algorithm from AusDiab was
used to classify cases in subtypes [25]. Subjects that started
their insulin treatment within two years of diagnosis were
classified as type 1. However, for subjects fulfilling these
criteria but with a age of 40 or above at onset, current BMI
had to be <27 to be classified as type 1. All other cases
were classified as type 2.
The Research Ethics Committee of Umeå University and
the National Computer Data Inspection Board have
approved the Northern Sweden MONICA Study.
Statistics
Means or medians are given for those who remained non-
diabetic and those who converted to diabetes. Because the
distributions for serum triglycerides, insulin and the fibri-
nolytic variables are highly skewed, we used logarithmi-
cally transformed values (i.e.  geometric means).
Differences between the two groups were compared by t-
test. The risk of incident diabetes was compared across
quartiles of the fibrinolytic variables, calculated from the
total sample. Chi-squares analysis with linear-to-linear
association was used. Logistic regression was used for cal-
culation of odds ratios and 95% confidence intervals (CI)
for the development of diabetes comparing the quartile
with highest risk with the other three pooled quartiles.
Stepwise adjustment for age and sex, waist, serum insulin,
triglycerides and diastolic blood pressure was used.
Results
At baseline, 754 subjects had an OGTT performed. Five
hundred and fifty-one subjects who initially had normal
glucose tolerance returned for re-examination. A new
OGTT was done in 477 of those with normal glucose tol-
erance and without clinically diagnosed diabetes. Thus,
there was no repeated OGTT in 13 %, mostly due to logis-
tic reasons such as not being able to turn up in the morn-
ing after an over night fast.
Among persons with initially normal glucose tolerance, in
all 15 subjects (2.7 %) had type 2 diabetes diagnosed,
either clinically (n = 4) or by OGTT (n = 11) after a 9-year
follow-up or 4,959 person years. The rough incidence was
3.0 cases/1000 person years. Fifty-one subjects (10,7 %)
worsened from normal glucose tolerance to impaired glu-
cose tolerance.
Baseline characteristics are given in Table 1. Converters
from NGT to diabetes were 7 years older and had higher
BMI and waist circumference. Diastolic blood pressure
did not differ but both fasting triglycerides, insulin, fast-
ing and post load plasma glucose were higher in subjects
with subsequent diabetes. Plasma levels of tPA antigen
and PAI-1 activity were higher and tPA activity was lower.
The risk of developing diabetes increased with increasing
quartiles of tPA antigen and PAI-1 activity and decreased
in a similar way for tPA activity (Figure 1). In the highest
quartile of tPA antigen (above 8.7 µg/l) nearly 9 % had
incident diabetes compared to none in the lowest
quartile.
Logistic regression was performed with an initial model
adjusting for age and sex. In a second model, waist
circumference was added and in a third model, also
Table 1: Baseline characteristics of subjects with normal glucose tolerance according to diabetes or not during 9 years of follow-up
Non-DM DM p-value
n 536 15
Age (years) 44.9 (10.9) 51.9 (8.7) 0.015
Sex (% men) 60 46 0.3
BMI (kg/m2) 25.0 (3.5) 28.4 (3.3) <0.001
Waist circumference (cm) 84.2 (11.0) 95.3 (9.8) <0.001
Diastolic blood pressure (mm Hg) 79.8 (10.7) 81.3 (10.8) 0.6
Triglycerides (mmol/l) 1.2 (0.9–1.7) [1.25] 2.1 (1.3–2.8) [1.95] < 0.001
Fasting plasma glucose (mmol/l) 5.16 (0.50) 5.89 (0.59) <0.001
Post load plasma glucose (mmol/l) 5.13 (1.12) 5.77 (1.04) 0.028
Fasting insulin (mU/ml) 5.0 (4.0–7.0) [5.7] 7.0 (8.0–10.0) [8.5] 0.002
tPA activity (IU/ml) 0.79 (0.56–1.0) [0.74] 0.59 (0.33–0.85) [0.54] 0.020
tPA antigen (µg/l) 5.7 (4.0 – 8.4) [5.7] 10.4 (9.0 – 13.7) [10.7] <0.001
PAI-1 activity (IU/ml) 6.1 (2.9 – 11.2) [6.2] 16.3 (7.1 – 18.8) [11.5] 0.003
Data are means (SD), median (interquartile range) and [geometric means]. P values are for t test, or X2 test as appropriate.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/19
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diastolic blood pressure, serum insulin and triglycerides
were added. Quartiles 1–3 of tPA antigen and PAI-1 activ-
ity were contrasted with the fourth quartile and, for tPA
activity, the first quartiles with quartile 2–4 (Table 2).
The lowest quartile of tPA activity was associated with a 3-
fold increase in the risk of diabetes, which was attenuated
after adjustment for waist circumference. After further
adjustment for diastolic blood pressure, fasting insulin
and triglycerides, no prediction from low tPA activity on
diabetes development was seen.
Subjects in the highest quartile of tPA antigen experienced
more than a ten-fold increase in risk, although the confi-
dence intervals were wide due to few cases. Taking waist
circumference into account, the odds ratio diminished to
6.7 and diminished further to 5.5 when adjusting for
blood pressure, triglycerides and insulin. However, addi-
tional adjustment for baseline fasting and post load
glucose increased the OR. The analysis was repeated using
BMI instead of waist circumference. This lead to some-
what higher age- and gender adjusted odds ratio (7.4; CI
1.8–30, p value 0.005). Exchanging diastolic with systolic
blood pressure did not change the findings. Furter adjust-
ment for leisure time physical activity reduced the odds
ratio from 5.5 to 5.1 (p value 0.03).
High PAI-1 activity increased the risk of diabetes four-
fold, although the result was attenuated to an insignifi-
cant OR of 2.0 when all factors were adjusted for
simultaneously.
The risk of developing diabetes or IGT during follow up (n
= 66) increased stepwise across quartiles of tPA antigen,
from 7.8% to 19.8% (p = 0,003, test for linear trend).
When adjusted for age and sex, the odds ratio for the high-
est vs. the three lower quartiles of tPA antigen was 1.9 (CI
1.01–1.6,  p  = 0.04) but diminished further when also
waist circumference was adjusted for, OR = 1.3 (CI 0.63–
6.5, p = 0.5).
Discussion
Subjects with normal glucose tolerance, who subse-
quently develop type 2 diabetes over the ensuing nine
years, are already at baseline characterised by impaired
fibrinolysis and endothelial dysfunction. Low tPA activity
and high PAI-1 activity is mainly explained by the pres-
ence of abdominal obesity but also by other metabolic
disturbances characteristic of the insulin resistance syn-
drome, such as high serum levels of triglycerides and insu-
lin. A novel finding, in this context, is that a high plasma
level of the endothelial-derived tPA is only slightly
explained by such factors. Thus, the development of type
2 diabetes is preceded by many years of perturbations in
fibrinolytic and endothelial function, which increases the
risk of atherothrombotic disease long before overt diabe-
tes is present.
PA1-1 is partly synthesised in fat cells and its activity is
strongly related to abdominal obesity as mirrored by high
waist circumference or WHR [26]. High circulating levels
of PAI-1 inhibit tPA released from the vessel walls and
lead to low levels of free tPA, i.e. low tPA activity and
impaired capability of thrombolysis. The only report of an
association between fibrinolysis and the development of
diabetes is a recent study where PAI-1 antigen was an
independent predictor of diabetes in American-Mexicans
that were followed up to 5 years [10]. There is no known
pathway whereby impaired fibrinolysis would increase
insulin resistance or decrease insulin release and our find-
ing that high PAI-1 and low tPA activity precedes diabetes
probably mirrors the strong relationship with intraab-
dominal fat and circulating levels of free fatty acids.
A recent experimental study show an almost three fold
increase in the level of PAI-1 antigen with an infusion of
triacylglycerol in healthy subjects without any impact on
tPA [27]. This effect was noted with constant levels of
insulin and glucose and also increased levels of soluble
vascular cell adhesion molecules-1 was found. This sup-
port our findings that adjustment for baseline triglyceride
levels, which were increased in converters, did not
Incidence of type 2 diabetes over nine years in subjects with  normal glucose tolerance according to baseline quartiles of  fibrinolytic variables Figure 1
Incidence of type 2 diabetes over nine years in sub-
jects with normal glucose tolerance according to 
baseline quartiles of fibrinolytic variables. The number 
of cases in each quartile for tPA activity was 7, 4, 3 and 1. 
Corresponding numbers for tPA antigen was 0, 1, 2 and 12 
and for PAI-1 activity 2, 1, 3 and 9, respectively. P values for 
X2 (linear by linear association) were 0.026 for tPA activity, 
<0,001 for tPA antigen and 0,007 for PAI-1 activity.
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significantly change the relationships noted for tPA anti-
gen but did decrease those for PAI-1.
tPA antigen has not previously been studied in prospec-
tive diabetes studies. A clear distinction is not possible
between markers of endothelial dysfunction and inflam-
matory markers [13]. It is thus possible that also tPA con-
centration is an inflammatory marker although we found
low correlations between tPA antigen and fibrinogen [24]
and highly sensitive CRP (own unpublished data).
Recently, it was described in type 2 diabetes patients, that
increased levels of tPA antigen, among other endothelial
markers, predicted the development of urinary albumin
excretion, a strong marker for CVD risk [28]. These find-
ings should be related to recent reports where inflamma-
tory markers predict the development of diabetes in
longitudinal studies. In most cases, this association was
diminished or vanished after indices of obesity were taken
into account. Pro-inflammatory substances derived from
abdominal fat tissue may be the common background for
these findings.
We therefore find it plausible that the relation between
high tPA and diabetes is a marker of some early distur-
bance in the vascular wall that operates independent of
obesity and inflammation. Already borderline hyperten-
sion is associated with high concentrations of tPA antigen,
even after adjustment for abdominal obesity, insulin and
triglycerides [29]. Thus, tPA mass may mirror an endothe-
lial dysfunction that is not causally related to the insulin
resistance syndrome but acts by a parallel pathogenetic
mechanism leading to atherothrombosis [30-32]. Insulin
resistance, on the other hand, is associated with endothe-
lial dysfunction and impaired vasodilatation due to
defects in endothelium-derived nitric oxide [33,34].
Taken together, these findings put focus on the role of the
vessel walls in the pathogenesis of type 2 diabetes.
The relevance of impaired fibrinolysis, i.e. low activity of
tissue plasminogen activator (tPA) or high activity of its
inhibitor (PAI-1), as independent risk factors for CVD is
unclear, as these variables seem to mirror most compo-
nents of the insulin resistance syndrome [21,26]. In some
studies, decreased fibrinolysis, as measured by high PAI-1
activity, has been associated with cardiovascular events
[15,16]. High levels of tPA antigen independently predict
cardiovascular events both in a healthy population
[16,17] and in patients with prevalent coronary disease
[18,19].
The major shortcoming of our study is the small number
of incident cases of diabetes leading to wide confidence
intervals. On the other hand, the odds ratios for tPA anti-
gen are high and consistent and based on a truly repre-
sentative population sample where basal normal glucose
tolerance was well defined, as were the incident cases of
diabetes. Thus, the risk of bias due to selection or case
ascertainment should be low. Admittedly, the lack of a
renewed OGTT in 13 % of the subjects could contribute to
some misclassifiaction and dilute the results somewhat.
An ongoing analysis of two more cohorts will serve to
extend our observations.
Table 2: Logistic regression analysis for fibrinolytic variables at baseline with incident type 2 diabetes as the dependent variable.
OR 95%CI p value
tPA activity Q2-4 vs Q1 2.7 (0.96–7.6) 0.059
Adjusted for age and sex 3.0 (1.03–8.6) 0.044
Adjusted for also for waist 1.7 (0.5–5.5) 0.4
Adjusted also for diastolic BP, 
fasting insulin and triglycerides
1.3 (0.4–4.6) 0.7
tPA antigen Q1-3, vs 4 13.0 (3.6–47) <0.001
Adjusted for age and sex 10.4 (2.7–40) 0.001
Adjusted for also for waist 6.7 (1.6–28) 0.009
Adjusted also for diastolic BP, 
fasting insulin and triglycerides
5.5 (1.2–25) 0.026
Adjusted also for fasting and 
postload glucose
6.5 (1.3–33) 0.024
PAI-1 activity, Q1-3, vs 4 4.8 (1.7–14) 0.004
Adjusted for age and sex 4.4 (1.5–13) 0.006
Adjusted for also for waist 2.8 (0.9–8.5) 0.08
Adjusted also for diastolic BP, 
fasting insulin and triglycerides
2.3 (0.6–8.7) 0.24
Q = quartile.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/19
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Conclusions
The early prediabetic state, with normal glucose tolerance,
is characterised by both impaired fibrinolysis and
endothelial dysfunction years before glucose levels
increase. Changes in endothelial function are independ-
ent from the insulin resistance syndrome and point
towards a distinctly different pathway both for cardiovas-
cular disease and for the development of diabetes. To
answer a classical question from 1990 [5] – Yes, the clock
for coronary heart disease seems to start ticking before the
onset of clinical diabetes!
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